Compare CMTL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | BTAI |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 49.2M |
| IPO Year | N/A | 2018 |
| Metric | CMTL | BTAI |
|---|---|---|
| Price | $3.21 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $32.80 |
| AVG Volume (30 Days) | 276.9K | ★ 658.3K |
| Earning Date | 01-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $499,528,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.15 | $544.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $1.17 |
| 52 Week High | $4.88 | $9.26 |
| Indicator | CMTL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 51.76 |
| Support Level | $3.00 | $1.82 |
| Resistance Level | $3.32 | $2.33 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 88.33 | 62.87 |
Comtech Telecommunications Corp is a provider of modern communications solution incorporated in USA. The company is engaged in designing, developing, producing and marketing products, systems, and services for communications solutions. It is engaged in two business segments, Satellite and Space Communications and Terrestrial and Wireless Networks. It's Space and satellite is USA based providers of modems and high-power amplifiers, a market leader in troposcatter technologies, and serves some of the world's defense contractors and allied foreign governments. Terrestrial and Wireless Networks segment is a provider of next generation 911 infrastructure and solutions for state and local governments and carriers. Majority of sales are generated from Satellite and Space Communications segment.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.